What clears athlete's foot? Antifungal creams work, and the evidence is solid

Athlete's foot is one of the few common nuisances where the honest answer is genuinely encouraging: an over-the-counter antifungal cream clears most cases, and the evidence behind that claim is unusually strong. About 15% of the world's population carries a fungal infection of the feet, and a Cochrane review of 67 trials found that the standard topical treatments cure the skin infection far more often than placebo [s1] [s2]. Athlete's foot — tinea pedis — most often appears between the toes or across the soles, causing itching, scaling and sometimes painful cracking [s2].

What the topical evidence shows

The topical review pooled placebo-controlled trials by drug class and reported the risk ratio of treatment failure — the chance a course leaves the infection uncured — where a number well below 1 means the drug works [s1]. Every class beat placebo decisively. Allylamines, the group that includes terbinafine, gave a risk ratio of treatment failure of 0.33 (95% confidence interval 0.24 to 0.44); azoles such as clotrimazole and miconazole gave 0.30 (0.20 to 0.45); ciclopirox olamine 0.27 (0.11 to 0.66); tolnaftate 0.19 (0.08 to 0.44); butenafine 0.33 (0.24 to 0.45); and undecanoates 0.29 (0.12 to 0.70) [s1]. In plain terms, all of them cut the failure rate to roughly a third of placebo or better.

Allylamines versus azoles

The one meaningful difference the review could pin down was between the two most familiar classes. A meta-analysis of 11 trials comparing allylamines directly with azoles gave a risk ratio of treatment failure of 0.63 (95% confidence interval 0.42 to 0.94) in favour of allylamines [s1]. That is a modest edge, not a rout: allylamines cure slightly more infections than azoles, and both are now sold without prescription [s1]. The reviewers' bottom line was that placebo-controlled trials of both classes "consistently produce much higher percentages of cure than placebo" [s1].

When pills come in

Oral antifungals are usually held back for chronic infection or when a cream has already failed [s2]. The oral review included 15 trials and 1438 participants and found terbinafine outperformed the older drug griseofulvin, with a pooled risk ratio of 2.26 (95% confidence interval 1.49 to 3.44) in favour of terbinafine's ability to cure [s2]. Two small placebo-controlled trials confirmed that the pills work: terbinafine gave a risk ratio of 24.54 (1.57 to 384.32) and itraconazole 6.67 (2.17 to 20.48) against placebo — figures whose enormously wide intervals reflect how few people were studied [s2]. No clear difference emerged between terbinafine and itraconazole [s2]. All the oral drugs reported side effects, most commonly gastrointestinal ones [s2].

The weak spot: nails

The good news stops at the skin. The topical review found the evidence for treating fungal nail infection much thinner, with topical ciclopirox olamine producing poor cure rates and creams needing to be applied daily for at least a year to have a chance [s1]. Nail infection can also reseed the skin, which is one reason athlete's foot recurs [s2]. Where the infection has moved into the nail, the simple cream story no longer holds, and the reviewers called for more research [s1].

What it adds up to

For an ordinary case of athlete's foot on the skin, the evidence supports a plain conclusion: a topical allylamine or azole cures the great majority of infections, allylamines have a small edge, and both are available over the counter [s1]. Oral treatment is effective too but is generally a second line for stubborn or failed disease, and it carries side effects a cream does not [s2]. Many of the oral trials were old, small and incompletely reported, with only one judged at low risk of bias, so the precise size of the drug differences is less certain than their direction [s2].

The trials enrolled people with infection confirmed under the microscope and by culture [s2], which is also the caution: not every itchy, scaling foot is fungal, and a rash that fails to clear on a proper antifungal course, spreads, or is accompanied by redness, swelling or diabetes-related foot risk is a reason to see a clinician rather than to keep buying creams. This article describes what the evidence shows, not what any individual should use.